TOP TIERMARKET NEWSWIRE
News & sentiment

DYNE THERAPEUTICS IN (DYN) — News & AI sentiment

DYNE THERAPEUTICS IN (DYN) news roundup. 19 stories in the past week, 25 over 30 days. Average 30-day sentiment is 42.2/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 18 sales totalling $113.8M — net selling of $113.8M. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →
24h stories
0
7d stories
19
avg sentiment 38.2/100
30d stories
25
avg sentiment 42.2/100
Insider net (90d)
$113.8M
0 buys · 18 sells
Congress (90d)
0
0 buys · 0 sells

DYN news in the last 24 hours, 7 days, 30 days and 90 days

How much DYN coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time windowDYN storiesAvg AI sentimentRead
Last 24 hours0no coverage
Last 7 days1938.2/100DYN headlines →
Last 30 days2542.2/100DYN headlines →
Last 90 days6645.4/100DYN headlines →

Latest stories on DYN

4d ago
4d ago
Dyne Therapeutics stock price target lowered to $30 by RBC Capital
Investing.com Analyst Ratings34 · bearishanalyst
4d ago
4d ago
4d ago
4d ago
4d ago
5d ago
5d ago
Dyne Therapeutics falls -15.4%
The Fly35 · bearishearnings
5d ago
Raymond James cuts Dyne Therapeutics price target on DM1 trial risk
Investing.com Analyst Ratings34 · bearishanalyst
5d ago
Dyne Therapeutics falls -22.3%
The Fly30 · bearishearnings
5d ago
5d ago
5d ago
5d ago
5d ago
5d ago
Dyne Therapeutics stock faces pressure after rival drug fails trial
Investing.com Analyst Ratings38 · neutralgeneral
5d ago
Why is Dyne Therapeutics stock plummeting today?
Investing.com Markets32 · bearishgeneral
5d ago
Sep 3
Sep 2
Sep 2
Aug 20
Aug 20
Wainwright reiterates Dyne Therapeutics stock rating on trial outlook
Investing.com Analyst Ratings56 · neutralanalyst
Aug 17
Open DYN in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →